<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="5135618a-f2f6-49bd-b0ea-636cb2adf84c"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use CYCLOSPORINE ophthalmic emulsion safely and effectively. See full prescribing information for CYCLOSPORINE ophthalmic emulsion.</content>
      <br/>
      <br/>
      <content styleCode="bold">CYCLOSPORINE ophthalmic emulsion, </content>
      <br/>
      <content styleCode="bold">For topical ophthalmic use</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 1983</content>
   </title>
   <effectiveTime value="20250217"/>
   <setId root="7bb2078d-17c2-4e6a-9f61-26c7ecbce945"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="116839699" root="1.3.6.1.4.1.519.1"/>
            <name>Devatis Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="643284938"/>
                  <name>Deva Holding A.S.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="502664398"/>
                        <name>Deva Holding A.S.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73043-005" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="ca3d14f9-b5cd-4f35-bd3f-b60504b67d34"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20240805"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="73043-005" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Cyclosporine</name>
                        <formCode code="C42913" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="EMULSION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>cyclosporine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="83HN0GTJ6D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CYCLOSPORINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="83HN0GTJ6D" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CYCLOSPORINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="71DD5V995L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOMER COPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="D5340Y2I9G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CASTOR OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.4"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-USE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator unit="1" value="3"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="73043-005-01" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20240704"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="0.4"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-USE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator unit="1" value="6"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="73043-005-02" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20240704"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA209811" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240704"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_7bb489e3-c02f-4ead-ab34-2d0eda7b9095">
               <id root="10e65df0-44c5-47fa-9c2a-fbe5a56cab09"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>Cyclosporine ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.</paragraph>
               </text>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Cyclosporine ophthalmic emulsion is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs. (<linkHtml href="#ID_7bb489e3-c02f-4ead-ab34-2d0eda7b9095">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_4092c2e1-444e-4f66-b745-303059edefdf">
               <id root="e9727c59-47b2-4b91-a462-ba4ad2628981"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <text>
                  <paragraph>Invert the unit dose vial a few times to obtain a uniform, white, opaque emulsion before using. Instill one drop of cyclosporine ophthalmic emulsion twice a day in each eye approximately 12 hours apart. Cyclosporine ophthalmic emulsion can be used concomitantly with lubricant eye drops, allowing a 15 minute interval between products. Discard vial immediately after use.</paragraph>
               </text>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Instill one drop of cyclosporine ophthalmic emulsion twice a day in each eye approximately 12 hours apart. </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_d589c2b5-d939-4ff2-a71b-e10787c27752">
               <id root="eff66565-dc77-44d8-83c4-865483dd1d4f"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Ophthalmic emulsion containing cyclosporine 0.5 mg/mL</paragraph>
               </text>
               <effectiveTime value="20240805"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Cyclosporine ophthalmic emulsion 0.5 mg/mL (<linkHtml href="#ID_d589c2b5-d939-4ff2-a71b-e10787c27752">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_138f2634-9bb0-4672-a5ef-9a025e562015">
               <id root="9e6e9911-b75c-4e25-b6f1-a647ba6f9577"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Cyclosporine ophthalmic emulsion is contraindicated in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.</paragraph>
               </text>
               <effectiveTime value="20240805"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>•Hypersensitivity (<linkHtml href="#ID_138f2634-9bb0-4672-a5ef-9a025e562015">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_7556a3be-dc01-41bc-a666-ee657f8a0601">
               <id root="baf978fd-2ea0-420c-9ee1-b91b07714962"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20240805"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>To avoid the potential for eye injury and contamination, be careful not to touch the vial tip to your eye or other surfaces. (<linkHtml href="#ID_920173dd-947b-40d9-86ad-d524da1b4171">5.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_920173dd-947b-40d9-86ad-d524da1b4171">
                     <id root="71d2861d-2313-44c5-911b-d0656320ffcf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Potential for Eye Injury and Contamination  </title>
                     <text>
                        <paragraph>Be careful not to touch the vial tip to your eye or other surfaces to avoid potential for eye injury and contamination.</paragraph>
                     </text>
                     <effectiveTime value="20240805"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_872e348a-a923-4ac3-b883-7a465d677e2b">
                     <id root="f32cd3b2-c84c-4bc6-b027-72df0c9f566b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Use with Contact Lenses  </title>
                     <text>
                        <paragraph>Cyclosporine ophthalmic emulsion should not be administered while wearing contact lenses. Patients with decreased tear production typically should not wear contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of cyclosporine ophthalmic emulsion.</paragraph>
                     </text>
                     <effectiveTime value="20240805"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_d086d12f-e61a-48f8-9b6a-63e125c69342">
               <id root="e8ea699f-ac62-4d94-997d-a29f25b84166"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following serious adverse reactions are described elsewhere in the labeling: </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Potential for Eye Injury and Contamination [<content styleCode="italics">see</content>
                        <content styleCode="italics">
                           <linkHtml href="#ID_920173dd-947b-40d9-86ad-d524da1b4171">Warnings and Precautions (5.1)</linkHtml>
                        </content>]</item>
                  </list>
               </text>
               <effectiveTime value="20250306"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reaction following the use of cyclosporine ophthalmic emulsion was ocular burning (17%). (<linkHtml href="#ID_8df601ca-b597-4f86-ad09-32f5161b4643">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Devatis, Inc. at 1-833-534-4406 or druginfo@devatis.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch or www.devatis.com.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_8df601ca-b597-4f86-ad09-32f5161b4643">
                     <id root="95297c9f-9451-477d-8b8b-7f5b7d62579a"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1	Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In clinical trials, the most common adverse reaction following the use of cyclosporine ophthalmic emulsion was ocular burning (17%).</paragraph>
                        <paragraph>Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).</paragraph>
                     </text>
                     <effectiveTime value="20250306"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_4aa3f8ec-c237-4653-b2ba-c9042ad6775a">
                     <id root="dfe696ff-65a0-4ca9-a898-31b019d4dbaf"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2	Post-marketing Experience  </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of cyclosporine ophthalmic emulsion. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>Reported reactions have included: hypersensitivity (including eye swelling, urticaria, rare cases of severe angioedema, face swelling, tongue swelling, pharyngeal edema, and dyspnea); and superficial injury of the eye (from the vial tip touching the eye during administration).</paragraph>
                     </text>
                     <effectiveTime value="20240805"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_bab43f50-26be-41bc-8936-743703885a61">
               <id root="a7f653a3-5f5c-4f8c-a7d4-4b07e62bc945"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20240805"/>
               <component>
                  <section ID="ID_bbce6304-9a0f-446b-8744-619f107c3d10">
                     <id root="7ebd8cef-153b-42b7-8491-09b1a6e06cad"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Clinical administration of cyclosporine ophthalmic emulsion 0.05% is not detected systemically following topical ocular administration [<content styleCode="italics">see <linkHtml href="#ID_31278314-ed53-43df-941a-29e8de441d47">Clinical Pharmacology (12.3)</linkHtml>
                           </content>], and maternal use is not expected to result in fetal exposure to the drug. Oral administration of cyclosporine to pregnant rats or rabbits did not produce teratogenicity at clinically relevant doses [<content styleCode="italics">see <linkHtml href="#ID_e7a9963a-444f-4483-b3a4-0ae3537964bc">Data</linkHtml>
                           </content>].</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                           <br/>
                           <content styleCode="underline">Animal Data</content>
                        </paragraph>
                        <paragraph>At maternally toxic doses (30 mg/kg/day in rats and 100 mg/kg/day in rabbits), cyclosporine oral solution (USP) was teratogenic as indicated by increased pre- and postnatal mortality, reduced fetal weight and skeletal retardations. These doses (normalized to body surface area) are 5,000 and 32,000 times greater, respectively, than the daily recommended human dose of one drop (approximately 28 mcL) of cyclosporine ophthalmic emulsion 0.05% twice daily into each eye of a 60 kg person (0.001 mg/kg/day), assuming that the entire dose is absorbed. No evidence of embryofetal toxicity was observed in rats or rabbits receiving cyclosporine during organogenesis at oral doses up to 17 mg/kg/day or 30 mg/kg/day, respectively. These doses in rats and rabbits are approximately 3,000 and 10,000 times greater, respectively, than the daily recommended human dose.</paragraph>
                        <paragraph>An oral dose of 45 mg/kg/day cyclosporine administered to rats from Day 15 of pregnancy until Day 21 postpartum produced maternal toxicity and an increase in postnatal mortality in offspring.</paragraph>
                        <paragraph>This dose is 7,000 times greater than the daily recommended human dose. No adverse effects in dams or offspring were observed at oral doses up to 15 mg/kg/day (2,000 times greater than the daily recommended human dose).</paragraph>
                     </text>
                     <effectiveTime value="20240805"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a0465a27-9355-4d27-abd3-41db5f74b2e1">
                     <id root="be99a198-8f1e-4e95-a1b4-ebecf7256ff1"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Cyclosporine is known to appear in human milk following systemic administration, but its presence in human milk following topical treatment has not been investigated. Although blood concentrations are undetectable following topical administration of cyclosporine ophthalmic emulsion <content styleCode="italics">[see <linkHtml href="#ID_31278314-ed53-43df-941a-29e8de441d47">Clinical Pharmacology (12.3)</linkHtml>]</content>, caution should be exercised when cyclosporine ophthalmic emulsion is administered to a nursing woman. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for cyclosporine ophthalmic emulsion and any potential adverse effects on the breast-fed child from cyclosporine.</paragraph>
                     </text>
                     <effectiveTime value="20240805"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_67df5975-14e0-4ae1-bebc-354495ac2e2f">
                     <id root="51b8d338-f33a-4bc5-8a2f-3112731671ff"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>Safety and efficacy have not been established in pediatric patients below the age of 16.</paragraph>
                     </text>
                     <effectiveTime value="20240805"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1152808e-4a5d-401d-826e-511ddcb2b242">
                     <id root="0be443f5-dd3a-497f-88ce-efad9a630627"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>No overall difference in safety or effectiveness has been observed between elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20240805"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8ae7cdd6-bf26-4064-938b-b78642f14563">
               <id root="9084d4a9-59b0-4203-9067-d1657a217bb7"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Cyclosporine ophthalmic emulsion 0.05% contains a topical calcineurin inhibitor immunosuppressant with anti-inflammatory effects. Cyclosporine’s chemical name is Cyclo[[(<content styleCode="italics">E</content>)-(2<content styleCode="italics">S</content>,3<content styleCode="italics">R</content>,4<content styleCode="italics">R</content>)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-2-aminobutyryl-<content styleCode="italics">N</content>-methylglycyl-<content styleCode="italics">N</content>-methyl-L-leucyl-L-valyl-<content styleCode="italics">N</content>-methyl-L-leucyl-L-alanyl-D-alanyl-<content styleCode="italics">N</content>-methyl-L-leucyl-<content styleCode="italics">N</content>-methyl-L-leucyl-<content styleCode="italics">N</content>-methyl-L-valyl] and it has the following structure:</paragraph>
                  <paragraph>Structural Formula</paragraph>
                  <renderMultiMedia referencedObject="mm1"/>
                  <paragraph>Formula: C<sub>62</sub>H<sub>111</sub>N<sub>11</sub>O<sub>12</sub>Mol. Wt.: 1202.6</paragraph>
                  <paragraph>Cyclosporine is fine white powder. Cyclosporine ophthalmic emulsion appears as a white opaque to slightly translucent homogeneous emulsion. It has an osmolality of 230 to 320 mOsmol/kg and a pH of 6.5-8.0. </paragraph>
                  <paragraph>Each mL of cyclosporine ophthalmic emulsion contains: <content styleCode="bold">Active:</content> cyclosporine 0.05%. <content styleCode="bold">Inactives:</content> glycerin; castor oil; polysorbate 80; carbomer copolymer type A; water for injection; and sodium hydroxide to adjust pH.</paragraph>
               </text>
               <effectiveTime value="20250306"/>
               <component>
                  <observationMedia ID="mm1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_66af20d0-37a6-4ebe-861e-503b22a8bf6b">
               <id root="b83c3133-c678-4136-bd9d-fb743a782b7e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20240805"/>
               <component>
                  <section ID="ID_c8ddc40b-66ce-4926-8754-27fc8c824344">
                     <id root="cdb565d5-7028-475e-b24a-4b6ec6640d31"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Cyclosporine is an immunosuppressive agent when administered systemically.</paragraph>
                        <paragraph>In patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca, cyclosporine emulsion is thought to act as a partial immunomodulator. The exact mechanism of action is not known.</paragraph>
                     </text>
                     <effectiveTime value="20240805"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_31278314-ed53-43df-941a-29e8de441d47">
                     <id root="61296641-f0d6-4de7-a297-d84dce26e79b"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>Blood cyclosporine A concentrations were measured using a specific high pressure liquid chromatography-mass spectrometry assay. Blood concentrations of cyclosporine, in all the samples collected, after topical administration of cyclosporine ophthalmic emulsion 0.05%, twice daily, in humans for up to 12 months, were below the quantitation limit of 0.1 ng/mL. There was no detectable drug accumulation in blood during 12 months of treatment with cyclosporine ophthalmic emulsion.</paragraph>
                     </text>
                     <effectiveTime value="20240805"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_416a2b9d-21db-4132-be95-dcfbde45c27e">
               <id root="f8b20426-e768-4f1b-94dd-83b7dbb35cd5"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20240805"/>
               <component>
                  <section ID="ID_bdf447f8-5898-456c-914b-9936e615f33a">
                     <id root="3c676a81-fd16-4120-a523-ac0512210f34"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <effectiveTime value="20240805"/>
                     <component>
                        <section ID="ID_5da71989-8cc3-4273-af0e-753079d1654d">
                           <id root="03e90720-c67b-4871-aa23-0f97f81e4835"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Carcinogenesis</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Systemic carcinogenicity studies were conducted in male and female mice and rats. In the 78-week oral (diet) mouse study, at doses of 1, 4, and 16 mg/kg/day, evidence of a statistically significant trend was found for lymphocytic lymphomas in females, and the incidence of hepatocellular carcinomas in mid-dose males significantly exceeded the control value.</paragraph>
                              <paragraph>In the 24-month oral (diet) rat study, conducted at 0.5, 2, and 8 mg/kg/day, pancreatic islet cell adenomas significantly exceeded the control rate in the low dose level. The hepatocellular carcinomas and pancreatic islet cell adenomas were not dose related. The low doses in mice and rats are approximately 80 times greater (normalized to body surface area) than the daily recommended human dose of one drop (approximately 28 mcL) of 0.05% cyclosporine ophthalmic emulsion twice daily into each eye of a 60 kg person (0.001 mg/kg/day), assuming that the entire dose is absorbed.</paragraph>
                           </text>
                           <effectiveTime value="20240805"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_a99cb06c-073a-47aa-9e45-9569462a3dbb">
                           <id root="5fc4cb85-39b1-4abd-8705-83c5258d654e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Mutagenesis</content>
                           </title>
                           <text>
                              <paragraph>Cyclosporine has not been found to be mutagenic/genotoxic in the Ames Test, the V79-HGPRT Test, the micronucleus test in mice and Chinese hamsters, the chromosome-aberration tests in Chinese hamster bone-marrow, the mouse dominant lethal assay, and the DNA-repair test in sperm from treated mice. A study analyzing sister chromatid exchange (SCE) induction by cyclosporine using human lymphocytes <content styleCode="italics">in vitr</content>o gave indication of a positive effect (i.e., induction of SCE).</paragraph>
                           </text>
                           <effectiveTime value="20240805"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_0daa6b20-1c4f-4a2f-9bda-662a25e1143a">
                           <id root="46c0abf1-8e07-4d83-acb3-9de1bd9cb85a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Impairment of Fertility</content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>No impairment in fertility was demonstrated in studies in male and female rats receiving oral doses of cyclosporine up to 15 mg/kg/day (approximately 2,000 times the human daily dose of 0.001 mg/kg/day normalized to body surface area) for 9 weeks (male) and 2 weeks (female) prior to mating.</paragraph>
                           </text>
                           <effectiveTime value="20240805"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_52e214c9-a0c1-462e-af0a-9a5752dd9985">
               <id root="965a76e0-449e-4dd3-bcbc-7f2cf6a20387"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <text>
                  <paragraph>Four multicenter, randomized, adequate and well-controlled clinical studies were performed in approximately 1,200 patients with moderate to severe keratoconjunctivitis sicca. Cyclosporine ophthalmic emulsion demonstrated statistically significant increases in Schirmer wetting of 10 mm versus vehicle at six months in patients whose tear production was presumed to be suppressed due to ocular inflammation. This effect was seen in approximately 15% of cyclosporine ophthalmic emulsion-treated patients versus approximately 5% of vehicle-treated patients. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.</paragraph>
                  <paragraph>No increase in bacterial or fungal ocular infections was reported following administration of cyclosporine ophthalmic emulsion.</paragraph>
               </text>
               <effectiveTime value="20240805"/>
            </section>
         </component>
         <component>
            <section ID="ID_616d9246-0eb6-4d5a-a1b8-534273bd742f">
               <id root="fbbc2871-b385-4aa4-9671-62db7c429eeb"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>Cyclosporine ophthalmic emulsion is packaged in sterile, preservative-free single-use vials. Each vial contains 0.4 mL fill in a 0.9 mL LDPE vial; 10 vials are packaged in an aluminum pouch. There are 3 (30 vials) or 6 (60 vials) pouches packaged per carton. The entire contents of each carton (30 vials or 60 vials) must be dispensed intact.<br/>
                     <br/>30 Vials 0.4 mL each – NDC 73043 005 01<br/>
                     <br/>60 Vials 0.4 mL each – NDC 73043 005 02</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage</content>: Store at 15°-25°C (59°-77°F).</paragraph>
               </text>
               <effectiveTime value="20240805"/>
            </section>
         </component>
         <component>
            <section ID="ID_40404f07-3b60-4cbe-8d3d-fd27efccd7c7">
               <id root="5d7f925f-42ae-49b7-af79-f404af88b100"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Handling the Container</content>
                  </paragraph>
                  <paragraph>Advise patients to not allow the tip of the vial to touch the eye or any surface, as this may contaminate the emulsion. Advise patients to not touch the vial tip to their eye to avoid the potential for injury to the eye [<content styleCode="italics">see </content>
                     <content styleCode="italics">
                        <linkHtml href="#ID_920173dd-947b-40d9-86ad-d524da1b4171">Warnings and Precautions (5.1)</linkHtml>
                     </content>]</paragraph>
                  <paragraph>
                     <content styleCode="bold">Use with Contact Lenses </content>
                  </paragraph>
                  <paragraph>Cyclosporine ophthalmic emulsion should not be administered while wearing contact lenses. Patients with decreased tear production typically should not wear contact lenses. Advise patients that if contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of cyclosporine ophthalmic emulsion [<content styleCode="italics">see <linkHtml href="#ID_872e348a-a923-4ac3-b883-7a465d677e2b">Warnings and Precautions (5.2)</linkHtml>
                     </content>].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Administration</content>
                  </paragraph>
                  <paragraph>Advise patients that the emulsion from one individual single-use vial is to be used immediately after opening for administration to one or both eyes, and the remaining contents should be discarded immediately after administration.</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250305"/>
            </section>
         </component>
         <component>
            <section ID="L4e8ecace-2d85-42dd-ba08-7d898490a96c">
               <id root="766f05cf-089c-4bc9-af33-253f7e253f45"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Made in Turkey</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                     <br/>Devatis, Inc.<br/>San Clemente, CA 92672<br/>
                     <br/>
                     <content styleCode="bold">KTP5463KT-03</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250217"/>
            </section>
         </component>
         <component>
            <section ID="ID_32918550-bae5-49f4-9a69-f42910e1f3c9">
               <id root="4897dde4-8c78-430e-95d3-ff0da3a709dd"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – 30 count carton</title>
               <text>
                  <paragraph>NDC 73043-<content styleCode="bold">005</content>-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">CycloSPORINE</content>
                     <br/>
                     <content styleCode="bold">Ophthalmic Emulsion, 0.05%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Use in the Eye</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 Single-Use Vials (0.4 mL Each)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile, Preservative-Free</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="mm2"/>
               </text>
               <effectiveTime value="20250217"/>
               <component>
                  <observationMedia ID="mm2">
                     <text>30 count carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f21103c8-3365-4de7-b05f-baefe0ec0887">
               <id root="5ea4fae4-6832-4699-b918-be2e71c81f24"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL – 60 count carton</title>
               <text>
                  <paragraph>NDC 73043-<content styleCode="bold">005</content>-02</paragraph>
                  <paragraph>
                     <content styleCode="bold">CycloSPORINE<br/>Ophthalmic Emulsion, 0.05%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For Use in the Eye</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">60 Single-Use Vials (0.4 mL Each)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile, Preservative-Free    </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="mm3"/>
               </text>
               <effectiveTime value="20250217"/>
               <component>
                  <observationMedia ID="mm3">
                     <text>60 count carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>